C. Llerena

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon et al. · The Lancet Respiratory Medicine · 2024 · 47 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Hélène Fricker‐Hidalgo, Bérangère Coltey, C. Llerena et al. · Clinical and Vaccine Immunology · 2010 · 44 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study

Noémie Coron, Marc Pihet, Émilie Fréalle et al. · Mycopathologia · 2017 · 44 citations

Medicine, Infectious Diseases, Pathology +15

<p>Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data</p>

Héloïse Rouzé, Marie Viprey, Samuel Allemann et al. · Patient Preference and Adherence · 2019 · 26 citations · Full text

Pharmacy, Pharmacotherapy, Pediatric Pharmacotherapy +16

Low influenza vaccination coverage in asthmatic children in France in 2006-7

F. Rancé, C. Chave, J. de Blic et al. · Eurosurveillance · 2008 · 22 citations · Full text

Public Health, Child Health, Infectious Diseases +14